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Abstract
C30H33F6N3S, triclinic, P1¯ (no. 2), a= 9.3012(5) Å,
b= 10.2734(5) Å, c= 15.1850(8) Å, α= 81.982(2)°,
β= 78.696(2)°, γ= 83.882(2)°, V = 1404.25(13) Å3, Z= 2,
Rgt(F)=0.0779, wRref(F2)=0.2499, T= 293(2) K.
CCDC no.: 1554490
The crystal structure is shown in the figure. Table 1 contains
crystallographicdata andTable 2 contains the list of the atoms
including atomic coordinates and displacement parameters.
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Table 1: Data collection and handling.
Crystal: Slab, colorless
Size: 0.58×0.47×0.07 mm
Wavelength: Mo Kα radiation (0.71073 Å)
µ: 0.18 mm−1
Diffractometer, scan mode: Bruker APEX-II, φ and ω-scans
θmax, completeness: 33.2°,>99%
N(hkl)measured, N(hkl)unique, Rint: 48368, 10750, 0.095
Criterion for Iobs, N(hkl)gt: Iobs > 2 σ(Iobs), 7424
N(param)refined: 398
Programs: Bruker programs [1], SHELX [2, 3],
ORTEP [4]
Table 2: Fractional atomic coordinates and isotropic or equivalent
isotropic displacement parameters (Å2).
Atom x y z Uiso*/Ueq
S1 0.98386(5) 0.51000(4) 0.66054(3) 0.01323(12)
N1 0.69696(17) 0.60257(15) 0.64402(11) 0.0122(3)
N2 0.86822(17) 0.75759(15) 0.62935(11) 0.0129(3)
N3 0.82652(17) 0.92552(15) 0.46515(11) 0.0141(3)
F1a 0.6835(5) 0.8971(3) 1.02509(18) 0.0589(9)
F2a 0.8013(4) 0.9811(2) 0.8977(2) 0.0610(9)
F3a 0.5984(4) 0.9168(3) 0.9015(2) 0.0706(9)
F1′b 0.8490(9) 0.9393(6) 0.9780(5) 0.0619(13)
F2′b 0.7236(12) 0.9677(7) 0.8762(5) 0.0598(14)
F3′b 0.6193(10) 0.8858(9) 1.0038(6) 0.0622(15)
F4 0.72337(19) 0.41464(15) 1.10754(9) 0.0349(4)
F5 0.8472(2) 0.29227(15) 1.01309(12) 0.0573(6)
F6 0.6274(3) 0.3624(2) 1.00252(14) 0.0643(7)
C1 0.82839(19) 0.62775(17) 0.64263(12) 0.0116(3)
C2 0.9920(2) 0.79314(18) 0.55694(13) 0.0150(3)
H2A 1.0694 0.7219 0.5558 0.018*
H2B 1.0313 0.8711 0.5692 0.018*
C3 0.9452(2) 0.81997(18) 0.46506(13) 0.0144(3)
H3A 1.0287 0.8450 0.4188 0.017*
H3B 0.9121 0.7403 0.4508 0.017*
C4 0.7000(2) 0.89565(18) 0.53841(13) 0.0148(3)
H4A 0.6542 0.8212 0.5262 0.018*
H4B 0.6276 0.9710 0.5404 0.018*
C5 0.7496(2) 0.86352(18) 0.62956(13) 0.0146(3)
H5A 0.7829 0.9422 0.6452 0.017*
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Table 2 (continued)
Atom x y z Uiso*/Ueq
H5B 0.6663 0.8377 0.6757 0.017*
C6 0.7924(2) 0.97605(18) 0.37967(14) 0.0156(4)
C7 0.6890(2) 1.08575(19) 0.37243(16) 0.0200(4)
H7 0.6424 1.1225 0.4243 0.024*
C8 0.6557(2) 1.1396(2) 0.28977(17) 0.0253(5)
H8 0.5862 1.2114 0.2867 0.030*
C9 0.7252(3) 1.0876(2) 0.21042(17) 0.0281(5)
H9 0.7018 1.1236 0.1548 0.034*
C10 0.8297(3) 0.9814(2) 0.21635(16) 0.0262(5)
H10 0.8783 0.9469 0.1640 0.031*
C11 0.8626(2) 0.9256(2) 0.29992(15) 0.0201(4)
H11 0.9323 0.8539 0.3026 0.024*
C12 0.63842(19) 0.47279(17) 0.66558(12) 0.0105(3)
C13 0.47856(19) 0.49282(17) 0.65042(13) 0.0131(3)
H13A 0.4230 0.5544 0.6899 0.016*
H13B 0.4769 0.5306 0.5884 0.016*
C14 0.4059(2) 0.36227(18) 0.66950(13) 0.0142(3)
H14 0.3044 0.3778 0.6592 0.017*
C15 0.4064(2) 0.30470(19) 0.76833(13) 0.0162(4)
H15A 0.3500 0.3650 0.8084 0.019*
H15B 0.3611 0.2217 0.7812 0.019*
C16 0.5654(2) 0.28244(19) 0.78459(13) 0.0152(3)
H16 0.5656 0.2454 0.8476 0.018*
C17 0.6379(2) 0.41381(18) 0.76491(12) 0.0139(3)
H17A 0.7380 0.3991 0.7758 0.017*
H17B 0.5840 0.4752 0.8051 0.017*
C18 0.7227(2) 0.37406(17) 0.60209(12) 0.0127(3)
H18A 0.7217 0.4103 0.5397 0.015*
H18B 0.8243 0.3595 0.6102 0.015*
C19 0.6515(2) 0.24254(17) 0.62253(13) 0.0135(3)
H19 0.7073 0.1803 0.5825 0.016*
C20 0.4927(2) 0.26407(18) 0.60698(13) 0.0149(3)
H20A 0.4478 0.1809 0.6198 0.018*
H20B 0.4911 0.2984 0.5443 0.018*
C21 0.6524(2) 0.18559(18) 0.72137(13) 0.0159(4)
H21A 0.7529 0.1701 0.7315 0.019*
H21B 0.6084 0.1019 0.7342 0.019*
C22 1.0637(2) 0.5927(2) 0.73707(13) 0.0160(4)
H22A 1.1509 0.5404 0.7517 0.019*
H22B 1.0929 0.6780 0.7070 0.019*
C23 0.9554(2) 0.61106(19) 0.82258(13) 0.0150(3)
C24 0.8961(2) 0.7359(2) 0.84203(14) 0.0205(4)
H24 0.9264 0.8099 0.8029 0.025*
C25 0.7908(3) 0.7504(2) 0.92038(15) 0.0243(4)
C26 0.7426(3) 0.6411(2) 0.97887(14) 0.0230(4)
H26 0.6706 0.6509 1.0300 0.028*
C27 0.8041(2) 0.5168(2) 0.95945(14) 0.0192(4)
C28 0.9100(2) 0.50135(19) 0.88264(13) 0.0167(4)
H28 0.9510 0.4174 0.8711 0.020*
C29a 0.7186(4) 0.8848(4) 0.9376(2) 0.0486(8)
C29′b 0.7479(9) 0.8848(11) 0.9475(5) 0.0535(10)
C30 0.7503(3) 0.3973(2) 1.02066(15) 0.0255(5)
Occupancies: a=0.716(3), b=284(3)
Source of material
3,5-Bis(trifluoromethyl)benzyl bromide (614 mg, 2.0 mmol)
and anhydrous potassium carbonate (276 mg, 2 mmol)
were added to an anhydrous acetone (15 mL) solution of
N -(adamantan-1-yl)-4-phenylpiperazine-1-carbothioamide
(711 mg, 2 mmol), and the mixture was heated under reflux
for 4 h. The solvent was then distilled off in vacuo and the
resulting residue was washed with water (20 mL), dried and
crystallized from aqueous ethanol to yield 872 mg (75%) of
the title compound as colourless crystals. M.pt: 386–388 K.
Single crystals suitable forX-ray analysiswere obtainedby the
slow evaporation of its CHCl3:EtOH (1:1; 5 mL) solution held at
room temperature. 1HNMR (CDCl3, 700.17 MHz): δ 1.58 (s, 6H,
adamantane-CH2), 1.69 (s, 6H, adamantane-CH2), 1.95−1.97
(m, 3H, adamantane-CH), 3.29–3.31 (m, 4H, piperazine-H),
3.40–3.42 (m, 4H, piperazine-H), 4.04 (s, 2H, benzylic CH2),
6.93–7.02 (m, 3H, Ar—H), 7.29 (s, 1H, Ar—H), 7.32–7.34 (m, 2H,
Ar—H), 7.78 (s, 2H, Ar—H). 13C{1H} NMR (CDCl3, 176.08 MHz):
δ 29.80, 35.51, 36.44, 54.80 (adamantane-C), 37.31 (benzylic
CH2), 49.0, 49.13 (piperazine-C), 116.28, 120.12, 129.16, 129.24,
131.44, 131.63, 141.30, 147.50 (Ar—C), 124.04 (CF3), 151.19 (C=N).
ESI-MS, m/z: 582.2 [M+H]+.
Experimental details
The C-bound H atoms were geometrically placed
(C—H=0.93–0.98 Å) and refined as riding with
U iso(H)= 1.2Ueq(C). Disorder was resolved for the C25-bound
CF3 group with two distinct sites modelled. The site occu-
pancy factor for the major component refined to 0.716(3).
Standard restraints in SHELXL [3], such as SADI and SIMU,
were employed. The maximum and minimum residual elec-
tron density peaks of 1.14 and 1.35 e Å−3, respectively,
were located 0.80 and 0.73 Å from the F1′ and S1 atoms,
respectively.
Discussion
Recently, a series of adamantane-isothiourea hybrid deriva-
tives were synthesized and demonstrated to exhibit a broad
spectrum of anti-bacterial activity [5]. The motivation for
the synthesis of these potential drugs was twofold. Firstly,
the adamantane cage, known to be highly lipophilic, is a
crucial pharmacophore in a number of drugs [6]. A key
example is that of the drug amantadine, an effective anti-
viral agent for influenza A viruses [7] as well as being a
potent anti-parkinsonian agent [8]. Subsequently, adaman-
tane derivatives have been shown to exhibit diversified
pharmocological potential, including anti-viral [9], anti-
cancer [10], anti-bacterial and anti-fungal [11], anti-malarial
[12] and anti-diabetic [13] activities. Secondly, and in the
same way, isothiourea derivatives are known to display
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significant anti-viral [14], anti-cancer [15] and anti-bacterial
[16] activities. With such a diverse range of pharmacologi-
cal profiles exhibited by both adamantane and isothiourea
derivatives, it was thought their combination through the syn-
thesis of adamantane-isothiourea hybrid molecules would
lead to even more efficient therapeutic agents [5]. Herein,
the crystal and molecular structures of the title compound
are described in continuation of complementary structural
studies of these new anti-bacterial agents [17].
The molecule [systematic name: 3,5-bis(trifluoromethyl)
benzyl 4-phenyl-N-(tricyclo[3.3.1.13,7]decan-1-yl)piperazine-1-
carboximidothioate] is shown in the figure (70% displace-
ment ellipsoids; the minor component of the disordered CF3
has been omitted). The central CN2S chromophore is strictly
planar with the r.m.s. deviation of the least-squares plane
through the C1, N1, N2 and S1 atoms being 0.0068 Å. There
is a Z configuration about the C1=N1 bond [1.272(2) Å], and
the piperazinyl ring has a chair conformation. The confor-
mational relationship between the central plane and the
piperazinyl ring approaches orthogonal with the dihedral
angle between the least-squares planes through the residues
being 70.42(7)°. The dihedral angle between the least-squares
planes through the piperazinyl and the N3-bound phenyl
ring is 28.47(6)°, indicating a twisted conformation. To a first
approximation, the di-substituted benzyl residue is folded
back over the rest of themolecule. Nevertheless, the residue is
inclined towards the piperazinyl group as reflected in the val-
ues of the C22—S1—C1—N2 and C22—S1—C1—N1 torsion angles
of 42.75(15) and−135.09(17)°, respectively. Generally the geo-
metric parameters are in the expected ranges [18, 19].
Themost prominent feature of themolecular packing are
weakmethylene-C—H· · ·N(piperazinyl) interactions between
centrosymmetrically related molecules [C2—H2b· · ·N3i:
H2b· · ·N3i = 2.53 Å, C2· · ·N3i = 3.444(2) Å with an angle
at H2b= 157° for symmetry operation i: 2 − x, 2− y, 1− z],
leading to dimeric aggregates. There are no other direc-
tional interactions connectingmolecules. Globally,molecules
assemble into double layers that stack along the c axis direc-
tion. The CF3 groups project to either side of the layers and
inter-digitate with successive layers. Reflecting the packing,
the calculatedHirshfeld surfaces [20, 21] showadominanceof
H· · ·H [48.6%], F· · ·H/H· · · F [28.1%], C· · ·H/H· · ·C [10.2%]
and F· · · F [6.3%] contacts to the overall surface.
There are two literature precedents for the title com-
pound, namely derivatives with 4-nitrobenzyl [5] and 4-
bromobenzyl [22] groups. There are non-trivial differences in
the conformations in these molecules. While there is nearly
an orthogonal relationship between the central plane and the
piperazinyl ring in the title structure, these residues are closer
to co-planar in the literature structures, with comparable
dihedral angles of 32.2(3) and 34.78(7)°, respectively.
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